| Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis (NCT06939582) | Xingchen Peng | 2024-12-22 |
| A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C. (NCT06742853) | AstraZeneca | 2024-12-20 |
| Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants (NCT07613684) | Epirium Bio Inc. | 2024-12-20 |
| A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants (NCT05367401) | Novartis Pharmaceuticals | 2024-12-20 |
| A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004) (NCT06688058) | Merck Sharp & Dohme LLC | 2024-12-20 |
| A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients (NCT07515209) | Huahui Health | 2024-12-20 |
| A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy. (NCT06701721) | Therini Bio Pty Ltd | 2024-12-20 |
| ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. (NCT06699576) | Hansoh BioMedical R&D Company | 2024-12-20 |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) (NCT06637423) | Merck Sharp & Dohme LLC | 2024-12-20 |
| Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant (NCT05670379) | Vivani Medical, Inc | 2024-12-20 |
| A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults (NCT06705569) | Pfizer | 2024-12-20 |
| Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors (NCT06806046) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2024-12-20 |
| Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD) (NCT06673069) | Ionis Pharmaceuticals, Inc. | 2024-12-20 |
| A Bioequivalence Study of JS005 Pre-filled Syringe and JS005 Auto-injector (NCT06732973) | Shanghai Junshi Bioscience Co., Ltd. | 2024-12-20 |
| A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants (NCT06745271) | Agios Pharmaceuticals, Inc. | 2024-12-20 |
| Nicotinic Acid for the Treatment of Alzheimer's Disease (NCT06582706) | Indiana University | 2024-12-19 |
| A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors (NCT06797336) | PAQ Therapeutics, Inc. | 2024-12-19 |
| Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 (NCT06714591) | SystImmune Inc. | 2024-12-19 |
| Spatially Fractionated Radiotherapy for Tumor Treatment (NCT07774819) | Xu Zhi-yuan | 2024-12-19 |
| A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma (NCT06604715) | Janssen Research & Development, LLC | 2024-12-19 |
| A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants (NCT06742086) | AbbVie | 2024-12-19 |
| Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL (NCT06631040) | Shahid Beheshti University of Medical Sciences | 2024-12-19 |
| A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers (NCT06577298) | CanSino Biologics Inc. | 2024-12-19 |
| Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas (NCT06540443) | MegaPro Biomedical Co. Ltd. | 2024-12-19 |
| Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases (NCT06238921) | H. Lee Moffitt Cancer Center and Research Institute | 2024-12-19 |
| Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer (NCT06305598) | Roswell Park Cancer Institute | 2024-12-19 |
| Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone (NCT07375654) | Cairo University | 2024-12-19 |
| Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004 (NCT06813781) | AstraZeneca | 2024-12-19 |
| ORKA-001 in Healthy Volunteers (NCT06698939) | Oruka Therapeutics, Inc. | 2024-12-19 |
| Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects (NCT06723691) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-12-18 |
| ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies (NCT06656494) | Beijing InnoCare Pharma Tech Co., Ltd. | 2024-12-18 |
| Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT07007910) | Haisco Pharmaceutical Group Co., Ltd. | 2024-12-18 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma (NCT06695026) | Rznomics, Inc. | 2024-12-18 |
| ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (NCT06588660) | University of Washington | 2024-12-18 |
| Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease (NCT05904093) | National Heart, Lung, and Blood Institute (NHLBI) | 2024-12-18 |
| A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012) (NCT06633419) | Merck Sharp & Dohme LLC | 2024-12-18 |
| NG004 in Spinal Cord Injury Patients (NCT06817577) | NovaGo Therapeutics AG | 2024-12-18 |
| A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease (NCT06753331) | Sumitomo Pharma America, Inc. | 2024-12-18 |
| A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity (NCT06737536) | Novo Nordisk A/S | 2024-12-18 |
| A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People (NCT06716190) | Boehringer Ingelheim | 2024-12-18 |
| Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (NCT06514261) | National Cancer Institute (NCI) | 2024-12-18 |
| A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis (NCT06713499) | Guangdong Hengrui Pharmaceutical Co., Ltd | 2024-12-18 |
| A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants (NCT06751017) | Shionogi | 2024-12-17 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis (NCT07667322) | Hoffmann-La Roche | 2024-12-17 |
| Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib (NCT06717100) | PureTech | 2024-12-17 |
| RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis (NCT06359041) | Cabaletta Bio | 2024-12-17 |
| Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 (NCT06672445) | Arrowhead Pharmaceuticals | 2024-12-17 |
| The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Injectable SPN01 in Phase I. (NCT06710561) | Beijing SonoPhotoNano Medical Technology Co., Ltd. | 2024-12-17 |
| Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors (NCT06727812) | Shandong Suncadia Medicine Co., Ltd. | 2024-12-17 |
| A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (NCT05989828) | University of Southern California | 2024-12-17 |
| A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004 (NCT06742762) | AstraZeneca | 2024-12-17 |
| Ixovex-1 Single Agent and Combination Therapy (NCT06549946) | Psivac Ltd | 2024-12-17 |
| A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors (NCT06725381) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2024-12-17 |
| APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST (NCT06687070) | Ascentage Pharma Group Inc. | 2024-12-17 |
| This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants (NCT06736912) | HK inno.N Corporation | 2024-12-16 |
| Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors (NCT06784193) | Olema Pharmaceuticals, Inc. | 2024-12-16 |
| Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation (NCT06501625) | Institut de Recherches Internationales Servier | 2024-12-16 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV (NCT06724640) | ViiV Healthcare | 2024-12-16 |
| A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors (NCT06747585) | Alentis Therapeutics AG | 2024-12-16 |
| Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106), Female Urinary Incontinence Women Over 50 Years Old (NCT06738576) | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 2024-12-16 |
| A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma (NCT06733441) | Treeline Biosciences, Inc. | 2024-12-16 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (NCT06488716) | Genentech, Inc. | 2024-12-16 |
| REACT-01: Reversing Autoimmunity Through Cell Therapy (NCT06465147) | Seattle Children's Hospital | 2024-12-16 |
| Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetic, and Food Effects of ARD-885 Film-coated Tablets in Healthy Chinese Subjects and Patients With Rheumatoid Arthritis (NCT07266207) | Artivila (Shenzhen) Innovation Center, Ltd | 2024-12-16 |
| Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects (NCT06730828) | Helios Cardio Inc. | 2024-12-16 |
| T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma (NCT06783270) | Inge Marie Svane | 2024-12-16 |
| Study of BM230 in Patients With Advanced Solid Tumors (NCT06644300) | Suzhou Biomissile Pharmaceuticals Co., Ltd. | 2024-12-16 |
| Prophylactic Intravenous Injection of Neostigmine Plus Atropine Versus Ketorolac on Post-dural Puncture Headache in Patients Undergoing Infraumbilical Surgeries (NCT06729047) | Assiut University | 2024-12-15 |
| Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis (NCT06628206) | LAPIX Therapeutics Inc. | 2024-12-15 |
| A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus (NCT06741982) | West China Hospital | 2024-12-15 |
| Intra-articular Allocetra in Osteoarthritis of the of the Temporomandibular Joint (TMJ) (NCT06748651) | Dr. Amit Druyan | 2024-12-15 |
| Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis (NCT06792344) | The Children's Hospital of Zhejiang University School of Medicine | 2024-12-15 |
| Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer (NCT06718738) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2024-12-15 |
| Gabapentin and Pressor Response to Intubation (NCT06705101) | Liaquat National Hospital & Medical College | 2024-12-15 |
| A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC (NCT06690671) | Shanghai Chest Hospital | 2024-12-15 |
| Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI (NCT06812221) | Biomind Labs Inc. | 2024-12-15 |
| Universal CNK-UT Therapy for Refractory aGVHD (NCT06750133) | First Affiliated Hospital of Zhejiang University | 2024-12-14 |
| Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors (NCT06621563) | Hansoh BioMedical R&D Company | 2024-12-14 |
| A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors (NCT06736327) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2024-12-13 |
| A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification (NCT06585488) | BeOne Medicines | 2024-12-13 |
| PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) (NCT06750432) | ProMis Neurosciences, Inc | 2024-12-13 |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (NCT06710847) | GlaxoSmithKline | 2024-12-13 |
| A Phase I Study of CFT8919 in Patients With Advanced NSCLC (NCT06641609) | Betta Pharmaceuticals Co., Ltd. | 2024-12-13 |
| Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors (NCT06663072) | University of Chicago | 2024-12-13 |
| A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants (NCT06692348) | Eli Lilly and Company | 2024-12-13 |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors (NCT06657222) | Tubulis GmbH | 2024-12-13 |
| Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment (NCT05460507) | Plus Therapeutics | 2024-12-12 |
| Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) (NCT06675864) | Novartis Pharmaceuticals | 2024-12-12 |
| Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets (NCT06610890) | Ganzhou Hemay Pharmaceutical Co., Ltd | 2024-12-12 |
| A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) (NCT06761586) | Aurigene Discovery Technologies Limited | 2024-12-12 |
| A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors (NCT06726369) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2024-12-12 |
| Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients (NCT06651866) | The First Affiliated Hospital of Xiamen University | 2024-12-12 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of G01 Eye Drops in Healthy Volunteers (NCT07779902) | Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. | 2024-12-12 |
| Study in Asymptomatic GRN-FTD Patients to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 (NCT06705192) | Mads Kjolby | 2024-12-12 |
| A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants (NCT06715683) | Bristol-Myers Squibb | 2024-12-12 |
| Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. (NCT06836505) | Sun Yat-Sen University Cancer Center | 2024-12-12 |
| A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer (NCT06768151) | Chongqing Precision Biotech Co., Ltd | 2024-12-12 |
| A Phase 1/2 Trial of ADI-270 in ccRCC (NCT06480565) | Adicet Therapeutics | 2024-12-12 |
| A Study of SIGX1094R in Patients With Advanced Solid Tumors (NCT06739291) | Signet Therapeutics | 2024-12-12 |
| A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma (NCT06669247) | Regeneron Pharmaceuticals | 2024-12-11 |